The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10439 malaria professionals are enjoying the free benefits of MalariaWorld today

methylene blue

NOT Open Access | Baseline and multinormal distribution of ex vivo susceptibilities of Plasmodium falciparum to methylene blue in Africa, 2013-18

May 19, 2020 - 14:32 -- NOT Open Access
Author(s): 
Gendrot M, Madamet M, Mosnier J, Fonta I, Amalvict R, Benoit N, Briolant S, Pradines B
Reference: 
J Antimicrob Chemother. 2020 May 14:dkaa174

Plasmodium falciparum resistance to most antimalarial compounds has emerged in Southeast Asia and spread to Africa. In this context, the development of new antimalarial drugs is urgent.

NOT Open Access | Pharmacokinetics and Ex vivo Antimalarial Activity of Artesunate-Amodiaquine plus Methylene Blue in Healthy Volunteers

January 27, 2020 - 13:47 -- NOT Open Access
Author(s): 
Anh CX, Chavchich M, Birrell GW, Van Breda K, Travers T, Rowcliffe K, Lord AR, Shanks GD, Edstein MD
Reference: 
Antimicrob Agents Chemother. 2020 Jan 6. pii: AAC.01441-19

High artesunate combination therapy (ACT) treatment failures of Plasmodium falciparum malaria in Southeast Asia has led to triple drug strategies to extend the useful life of ACTs. In this study, we determined whether methylene blue (MB) alters the pharmacokinetics of artesunate-amodiaquine (ASAQ) and enhances the ex vivo antimalarial activity of ASAQ. In an open labelled, randomized cross-over design, a single oral dose of either ASAQ (200 mg AS/540 mg AQ) alone or with MB (325 mg MB) was administered to 15 healthy Vietnamese volunteers. Serial blood samples were collected up to 28 days after dosing.


Subscribe to RSS - methylene blue